The IPO of Mankind Pharma was off the mark on Tuesday but the issue saw a muted response from the investors during the initial two hours of the book-building process.
A majority of the brokerage firms are positive on the issue and suggest investors subscribe to the issue on a long-term basis, but some analysts have raised red flags over rich valuations and complete OFS nature.